首頁 > 市場調查報告書 > 製藥

處方藥

市場調查報告書

商品編碼

1832723

骨髓纖維化治療市場報告：2031 年趨勢、預測與競爭分析

Myelofibrosis Targeted Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

出版日期: 2025年10月06日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄圖表

全球骨髓纖維化治療市場前景光明，原發性纖維化和次發性骨髓纖維化市場都蘊藏著機會。預計2025年至2031年，全球骨髓纖維化治療市場將以4.1%的複合年成長率成長。該市場的主要驅動力是原發性纖維化盛行率的上升以及對有效治療方案的需求。

根據Lucintel的預測，預計預測期內蘆可替尼在類型方面將經歷高速成長。
根據應用，原發性骨髓纖維化預計將出現高速成長。
按地區分類，預計亞太地區將在預測期內實現最高成長。

骨髓纖維化治療市場的新趨勢

全球骨髓纖維化治療市場的新趨勢正在重塑醫療保健系統應對這種罕見血癌的方式。個人化療法的開發、JAK抑制劑的進展以及新型聯合療法等關鍵趨勢正在改善患者的治療效果。隨著疾病格局的演變，這些趨勢為標靶藥物市場的創新和成長提供了巨大的機會。

JAK抑制劑療法的進展：JAK抑制劑，例如蘆可替尼，已成為骨髓纖維化治療的支柱。正在進行的研究旨在提高這些藥物的療效，特別是針對對現有治療方法有抗藥性或不耐受的患者。下一代JAK抑制劑將具有更強的療效、更少的副作用、更高的患者依從性，並顯著擴展治療選擇。
個人化醫療和精準醫療：隨著基因分析和基於生物標記的檢測日益普及，個人化醫療在骨髓纖維化治療中日益受到重視。個人化醫療使醫療保健提供者能夠根據個別基因組成客製化治療方案，從而提高療效並最大程度地減少副作用。這一趨勢正在推動標靶治療的發展，以改善患者的預後。
聯合治療：聯合治療治療方法解決骨髓纖維化的複雜病理生理機制，並提供更全面的治療方法。聯合治療有望改善患者的生存率和生活品質。
監管支持和核准加大：隨著人們對骨髓纖維化認知的不斷提高，監管機構正在加速新藥的核准。世界各國政府正在加強獎勵，鼓勵製藥公司開發針對罕見疾病的標靶治療。這些監管方面的進步正在縮短從臨床試驗到上市的時間，為全球骨髓纖維化患者提供更多獲得最先進治療的機會。
全球市場擴張：新興市場（尤其是亞洲和非洲）標靶治療的日益普及是一個重要趨勢。低成本學名藥以及與本地製造商的策略合作正在改善人們獲得救命治療的途徑。全球市場擴張預計將顯著改善醫療資源匱乏地區的治療可近性和醫療保健可近性。

JAK抑制劑的進展、個人化醫療、聯合治療、監管格局以及不斷擴張的全球市場等新興趨勢，將有望改變骨髓纖維化治療的格局。這些趨勢正在透過推動創新、改善患者照護和增加治療可及性，重塑全球骨髓纖維化治療市場的未來。

骨髓纖維化藥物市場的最新趨勢

隨著創新藥物的核准、臨床試驗的持續進行以及新型治療方法的不斷研發，骨髓纖維化治療市場正在快速發展。這些關鍵進展正在重塑治療方案，改善患者預後，並在全球擴大有效治療方法的可及性。

Fedratinib（Inrebic）核准：JAK2抑制劑Fedratinib已獲FDA核准用於治療中危險群2型或高危險群骨髓纖維化患者。此項核准為對蘆可替尼不耐受或抗藥性的患者提供了一個重要的治療選擇。 Fedratinib的上市豐富了骨髓纖維化的治療選擇，並改善了患者的預後。
魯索替尼（Jakafi）適應症擴大：魯索替尼仍然是治療骨髓纖維化的關鍵藥物。近期研究表明，其療效不僅限於骨髓纖維化，還涵蓋真性紅血球增多症患者。魯索替尼核准的擴大顯著改善了多種血液系統疾病的治療。
新型JAK抑制劑正在研發中：包括帕克替尼和莫米洛替尼在內的幾種新型JAK抑制劑正在臨床研發中。這些藥物旨在為骨髓纖維化患者（尤其是對蘆可替尼無反應的患者）提供更佳的耐受性和更高的療效。下一代JAK抑制劑可望為患者拓展治療選擇。
幹細胞和基因療法臨床試驗：針對骨髓纖維化的幹細胞和基因療法的臨床試驗正在蓬勃發展。這些方法可能帶來更持久的緩解。幹細胞移植已成為治療方法的一部分，而基因治療被認為是未來在分子層面治療骨髓纖維化的方法。
提升全球治療可及性：包括魯索替尼在內的骨髓纖維化藥物的學名藥核准，正在擴大全球標靶治療的可及性。製藥公司正在與新興市場的組織合作，以擴大可負擔藥物的可近性。這種可近性的擴大有助於改善醫療資源匱乏地區病患的治療效果。

費德拉替尼等新藥的核准、蘆可替尼適應症的擴大、下一代 JAK 抑製劑的開發以及幹細胞和基因治療的進步是推動骨髓纖維化治療市場的主要發展，這些發展改善了患者護理，增加了治療機會，並在全球範圍內擴大了治療選擇。

The future of the global myelofibrosis targeted drug market looks promising with opportunities in the primary myelofibrosis, and secondary myelofibrosis markets. The global myelofibrosis targeted drug market is expected to grow with a CAGR of 4.1% from 2025 to 2031. The major drivers for this market are increasing prevalence of primary myelofibrosis and demand for effective treatments. and advancements in targeted therapies improving patient outcomes and survival rates..

Lucintel forecasts that, within the type category, ruxolitinib is expected to witness higher growth over the forecast period.
Within the application category, primary myelofibrosis is expected to witness the higher growth.
In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Myelofibrosis Targeted Drug Market

Emerging trends in the global myelofibrosis targeted drug market are reshaping the way healthcare systems address this rare hematological cancer. Key trends such as the development of personalized therapies, JAK inhibitor advancements, and new combination treatments are improving patient outcomes. As the disease landscape evolves, these trends offer substantial opportunities for innovation and growth in the targeted drug market.

Advances in JAK Inhibitor Therapies: JAK inhibitors like ruxolitinib have become central to myelofibrosis treatment. Ongoing research aims to improve the efficacy of these drugs, particularly in patients with resistance or intolerance to existing treatments. The next generation of JAK inhibitors offers enhanced potency, fewer side effects, and better patient adherence, significantly expanding treatment options.
Personalized and Precision Medicine: The focus on personalized medicine in myelofibrosis treatment is growing, with genetic profiling and biomarker-based testing becoming more prevalent. Personalized treatments enable healthcare providers to tailor therapy based on an individual's genetic makeup, improving efficacy and minimizing adverse effects. This trend is fostering the development of targeted therapies that offer better patient outcomes.
Combination Therapy Approaches: Combination therapies, such as JAK inhibitors combined with other novel agents like immune modulators, are showing promise in clinical trials. These therapies aim to address the complex pathophysiology of myelofibrosis, providing a more comprehensive treatment approach. Combination therapies are anticipated to improve survival rates and patient quality of life.
Increased Regulatory Support and Approvals: With growing awareness of myelofibrosis, regulatory agencies are fast-tracking approvals for novel drugs. Governments are providing more incentives for pharmaceutical companies to develop targeted therapies for rare diseases. These regulatory advancements are reducing the time from clinical trials to market availability, increasing access to cutting-edge therapies for myelofibrosis patients worldwide.
Global Market Expansion: The increasing availability of targeted drugs in emerging markets, especially in Asia and Africa, is a significant trend. Lower-cost generics and strategic collaborations with local manufacturers are improving access to life-saving treatments. The global market expansion is expected to significantly increase treatment availability and healthcare access in underserved regions.

The emerging trends of JAK inhibitor advancements, personalized medicine, combination therapies, regulatory support, and global market expansion are poised to revolutionize the treatment landscape for myelofibrosis. These trends are driving innovation, improving patient care, and providing greater accessibility to therapies, thus reshaping the future of the global myelofibrosis targeted drug market.

Recent Developments in the Myelofibrosis Targeted Drug Market

The myelofibrosis targeted drug market is evolving rapidly due to innovative drug approvals, ongoing clinical trials, and the development of novel therapies. These key developments are reshaping treatment options, improving patient outcomes, and expanding access to effective therapies globally.

Approval of Fedratinib (Inrebic): Fedratinib, a JAK2 inhibitor, was approved by the FDA for the treatment of intermediate-2 or high-risk myelofibrosis patients. This approval offers an important alternative for patients who are intolerant or resistant to ruxolitinib. The availability of fedratinib is helping diversify treatment options for myelofibrosis and improving patient outcomes.
Ruxolitinib (Jakafi) Expansion: Ruxolitinib continues to be a cornerstone therapy for myelofibrosis. Recent studies show that its effectiveness extends beyond myelofibrosis, also benefiting patients with polycythemia vera. The approval of ruxolitinib for expanded indications is significantly improving the treatment landscape for various blood disorders.
New JAK Inhibitors in Development: Several new JAK inhibitors, including pacritinib and momelotinib, are in clinical development. These drugs aim to offer better tolerability profiles and greater efficacy in patients with myelofibrosis, particularly those who do not respond to ruxolitinib. The next generation of JAK inhibitors is expected to expand treatment options for patients.
Stem Cell and Gene Therapy Trials: Clinical trials investigating stem cell and gene therapies for myelofibrosis are gaining traction. These approaches offer the potential for more durable, long-term remission. Stem cell transplants are already part of the treatment arsenal, and gene therapy is seen as the future of treating myelofibrosis at a molecular level.
Increased Global Access to Treatments: With the growing approval of generics for myelofibrosis drugs, including ruxolitinib, access to targeted therapies is expanding globally. Pharmaceutical companies are partnering with organizations in emerging markets to ensure wider distribution of affordable drugs. This increase in access is helping improve patient outcomes in underserved regions.

The approval of new drugs like fedratinib, the expansion of ruxolitinib's indications, the development of next-generation JAK inhibitors, and advancements in stem cell and gene therapy are key developments driving the myelofibrosis targeted drug market. These developments are improving patient care, increasing access to treatments, and expanding therapeutic options globally.

Strategic Growth Opportunities in the Myelofibrosis Targeted Drug Market

The global myelofibrosis targeted drug market presents several strategic growth opportunities, particularly in emerging markets, through the development of new therapies and improved access to existing treatments. Pharmaceutical companies have the chance to capitalize on these opportunities by targeting key patient demographics, expanding drug availability, and pursuing innovative research avenues.

Emerging Market Penetration: Emerging markets such as China, India, and Southeast Asia offer significant growth potential for myelofibrosis treatments. Pharmaceutical companies can expand their reach by introducing affordable, generic versions of targeted therapies like ruxolitinib and by establishing partnerships with local healthcare providers to enhance distribution.
Focus on Combination Therapies: Companies that invest in combination therapies targeting multiple pathways involved in myelofibrosis progression will likely find a competitive advantage. By offering treatment regimens that combine JAK inhibitors with novel agents like immunomodulators, companies can improve overall treatment efficacy and patient outcomes, which can attract a broader market.
Personalized Treatment Solutions: Personalized medicine, especially the use of genetic profiling, will play a significant role in the treatment of myelofibrosis. Companies that develop therapies based on patient-specific genetic and molecular markers will be able to target the most appropriate treatments, enhancing the effectiveness of drugs and improving patient outcomes.
Regulatory Approvals in Key Markets: Expediting the approval process for new treatments and focusing on gaining regulatory clearance in underserved regions will present growth opportunities. Pharmaceutical companies can navigate regulatory pathways more effectively by working closely with local authorities, enabling quicker market entry and faster patient access to therapies
Investment in Clinical Trials and Research: There is a growing opportunity for pharmaceutical companies to invest in research for innovative treatments, including stem cell therapy, gene therapy, and next-generation JAK inhibitors. By leading clinical trials and focusing on breakthrough therapies, companies can position themselves as leaders in the myelofibrosis treatment landscape.

The global myelofibrosis targeted drug market offers numerous growth opportunities, including expansion in emerging markets, combination therapy development, personalized treatment solutions, regulatory approvals, and ongoing clinical research. These strategies can help companies increase their market share and provide better treatment options for patients with myelofibrosis.

Myelofibrosis Targeted Drug Market Driver and Challenges

The growth of the global myelofibrosis targeted drug market is influenced by a range of drivers, including advancements in drug development and increasing awareness. However, challenges such as high drug costs, regulatory hurdles, and access in underserved regions remain key factors shaping the market's trajectory.

The factors responsible for driving the Myelofibrosis Targeted Drug market include:

1. Advancements in Targeted Therapies: The development of JAK inhibitors and other targeted therapies has significantly improved treatment outcomes for myelofibrosis patients. These therapies address the root cause of the disease, making treatment more effective and driving market growth.

2. Increased Research Funding: Government and private sector investments in research are accelerating the development of new treatments. Financial support for clinical trials and drug development is helping bring novel therapies to market faster.

3. Rising Awareness of Myelofibrosis: Increased awareness about myelofibrosis, particularly in high-risk populations, is driving earlier diagnoses and higher demand for treatments. Awareness campaigns and educational initiatives are helping to identify more cases and reduce diagnostic delays.

4. Aging Population: As the global population ages, the incidence of myelofibrosis is increasing, particularly in older adults. This demographic trend is fueling demand for more effective treatments and driving growth in the targeted drug market.

5. Regulatory Support for Rare Diseases: Many governments are offering fast-track approval processes and incentives for rare disease treatments, making it easier for companies to bring new drugs to market. This support is accelerating the development of new therapies for myelofibrosis.

Challenges in the Myelofibrosis Targeted Drug market are:

1. High Cost of Treatment: The cost of targeted therapies remains a barrier to access, especially in low-income countries. High drug prices and the financial burden on patients limit the market's potential.

2. Regulatory Delays: The long regulatory approval process in certain markets can delay the availability of novel treatments. Companies must navigate complex regulatory environments to gain market approval for their products.

3. Limited Access in Rural Areas: Despite advancements, access to myelofibrosis treatments remains limited in rural and underserved regions. Poor healthcare infrastructure and distribution challenges prevent patients from receiving timely treatment.

While advancements in targeted therapies, increased research funding, and government support are driving growth in the myelofibrosis drug market, challenges such as high treatment costs, regulatory hurdles, and access limitations remain significant barriers. Addressing these challenges will be key to unlocking the full potential of this market.

List of Myelofibrosis Targeted Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies myelofibrosis targeted drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the myelofibrosis targeted drug companies profiled in this report include-

Novartis
Celgene
Incyte
Zelgen
GSK Plc

Myelofibrosis Targeted Drug Market by Segment

The study includes a forecast for the global myelofibrosis targeted drug market by type, application, and region.

Myelofibrosis Targeted Drug Market by Type [Value from 2019 to 2031]:

Ruxolitinib
Jaktinib
Fedratinib
Pacritinib
Others

Myelofibrosis Targeted Drug Market by Application [Value from 2019 to 2031]:

Primary Myelofibrosis
Secondary Myelofibrosis

Myelofibrosis Targeted Drug Market by Region [Value from 2019 to 2031]:

North America
Europe
Asia Pacific
The Rest of the World

Country Wise Outlook for the Myelofibrosis Targeted Drug Market

The global myelofibrosis targeted drug market is experiencing significant growth due to increasing research and advancements in targeted therapies for this rare and debilitating blood cancer. Myelofibrosis, a type of bone marrow disorder, has seen notable developments in the form of novel drug treatments, improving patient outcomes and providing new hope for effective management. This is particularly evident in key markets like the United States, China, Germany, India, and Japan.

United States: The United States remains at the forefront of the myelofibrosis targeted drug market, driven by the high incidence of the disease and strong investments in research and development. Recent approvals for novel JAK inhibitors, such as ruxolitinib and fedratinib, have transformed the treatment landscape. Additionally, ongoing clinical trials exploring combination therapies, such as JAK inhibitors combined with other novel agents, are likely to drive future innovations. Furthermore, the increasing adoption of personalized medicine is expected to offer tailored treatment options for myelofibrosis patients.
China: China's myelofibrosis targeted drug market is expanding due to rising healthcare access and improved diagnostic infrastructure. The Chinese government's focus on expanding oncology treatments has led to the approval of several targeted therapies in recent years. With a growing aging population and increased awareness, the demand for myelofibrosis treatments, particularly JAK inhibitors, is on the rise. Additionally, multinational pharmaceutical companies are exploring collaborations with local Chinese manufacturers to increase drug availability and market penetration.
Germany: Germany is a key player in the European myelofibrosis drug market, benefiting from a robust healthcare system and a high rate of medical advancements. The approval of ruxolitinib and other targeted therapies has improved survival rates for myelofibrosis patients. The market is driven by the country's strong emphasis on precision medicine and the integration of genetic testing into clinical practices. The German government's healthcare policies also support the reimbursement of myelofibrosis drugs, ensuring broader patient access to life-saving treatments.
India: In India, the myelofibrosis targeted drug market is emerging due to the increasing diagnosis of hematological disorders and the availability of cost-effective treatments. However, challenges remain in terms of drug affordability and access, particularly in rural areas. Despite this, the Indian pharmaceutical industry's growing capacity to produce generic versions of targeted therapies, including ruxolitinib, is driving market growth. With rising awareness and improvements in healthcare infrastructure, the market for myelofibrosis therapies in India is expected to continue expanding.
Japan: Japan is witnessing steady growth in the myelofibrosis targeted drug market, driven by high healthcare standards and the increasing aging population. Japan was one of the first countries to approve ruxolitinib for myelofibrosis treatment, and it remains a leader in adopting innovative therapies. The Japanese government has been supportive of expanding the oncology drug market, and there are ongoing efforts to integrate novel therapies such as JAK inhibitors and stem cell treatments into standard care for myelofibrosis.

Features of the Global Myelofibrosis Targeted Drug Market

Market Size Estimates: Myelofibrosis targeted drug market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Myelofibrosis targeted drug market size by type, application, and region in terms of value ($B).
Regional Analysis: Myelofibrosis targeted drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the myelofibrosis targeted drug market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the myelofibrosis targeted drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the myelofibrosis targeted drug market by type (ruxolitinib, jaktinib, fedratinib, pacritinib, and others), application (primary myelofibrosis and secondary myelofibrosis), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global Myelofibrosis Targeted Drug Market by Type

4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Ruxolitinib: Trends and Forecast (2019-2031)
4.4 Jaktinib: Trends and Forecast (2019-2031)
4.5 Fedratinib: Trends and Forecast (2019-2031)
4.6 Pacritinib: Trends and Forecast (2019-2031)
4.7 Others: Trends and Forecast (2019-2031)

5. Global Myelofibrosis Targeted Drug Market by Application

5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Primary Myelofibrosis: Trends and Forecast (2019-2031)
5.4 Secondary Myelofibrosis: Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview
6.2 Global Myelofibrosis Targeted Drug Market by Region

7. North American Myelofibrosis Targeted Drug Market

7.1 Overview
7.2 North American Myelofibrosis Targeted Drug Market by type
7.3 North American Myelofibrosis Targeted Drug Market by application
7.4 United States Myelofibrosis Targeted Drug Market
7.5 Mexican Myelofibrosis Targeted Drug Market
7.6 Canadian Myelofibrosis Targeted Drug Market

8. European Myelofibrosis Targeted Drug Market

8.1 Overview
8.2 European Myelofibrosis Targeted Drug Market by type
8.3 European Myelofibrosis Targeted Drug Market by application
8.4 German Myelofibrosis Targeted Drug Market
8.5 French Myelofibrosis Targeted Drug Market
8.6 Spanish Myelofibrosis Targeted Drug Market
8.7 Italian Myelofibrosis Targeted Drug Market
8.8 United Kingdom Myelofibrosis Targeted Drug Market

9. APAC Myelofibrosis Targeted Drug Market

9.1 Overview
9.2 APAC Myelofibrosis Targeted Drug Market by type
9.3 APAC Myelofibrosis Targeted Drug Market by application
9.4 Japanese Myelofibrosis Targeted Drug Market
9.5 Indian Myelofibrosis Targeted Drug Market
9.6 Chinese Myelofibrosis Targeted Drug Market
9.7 South Korean Myelofibrosis Targeted Drug Market
9.8 Indonesian Myelofibrosis Targeted Drug Market

10. ROW Myelofibrosis Targeted Drug Market

10.1 Overview
10.2 ROW Myelofibrosis Targeted Drug Market by type
10.3 ROW Myelofibrosis Targeted Drug Market by application
10.4 Middle Eastern Myelofibrosis Targeted Drug Market
10.5 South American Myelofibrosis Targeted Drug Market
10.6 African Myelofibrosis Targeted Drug Market

11. Competitor Analysis

11.1 Product Portfolio Analysis
11.2 Operational Integration
11.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis
12.2 Growth Opportunity Analysis
- 12.2.1 Growth Opportunities by Type
- 12.2.2 Growth Opportunities by Application
12.3 Emerging Trends in the Global Myelofibrosis Targeted Drug Market
12.4 Strategic Analysis
- 12.4.1 New Product Development
- 12.4.2 Certification and Licensing
- 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis
13.2 Novartis
- Company Overview
- Myelofibrosis Targeted Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.3 Celgene
- Company Overview
- Myelofibrosis Targeted Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.4 Incyte
- Company Overview
- Myelofibrosis Targeted Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.5 Zelgen
- Company Overview
- Myelofibrosis Targeted Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.6 GSK Plc
- Company Overview
- Myelofibrosis Targeted Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

14. Appendix

14.1 List of Figures
14.2 List of Tables
14.3 Research Methodology
14.4 Disclaimer
14.5 Copyright
14.6 Abbreviations and Technical Units
14.7 About Us
14.8 Contact Us

簡介目錄圖表

List of Figures

Figure 1.1: Trends and Forecast for the Global Myelofibrosis Targeted Drug Market
Figure 2.1: Usage of Myelofibrosis Targeted Drug Market
Figure 2.2: Classification of the Global Myelofibrosis Targeted Drug Market
Figure 2.3: Supply Chain of the Global Myelofibrosis Targeted Drug Market
Figure 3.1: Driver and Challenges of the Myelofibrosis Targeted Drug Market
Figure 3.2: PESTLE Analysis
Figure 3.3: Patent Analysis
Figure 3.4: Regulatory Environment
Figure 4.1: Global Myelofibrosis Targeted Drug Market by Type in 2019, 2024, and 2031
Figure 4.2: Trends of the Global Myelofibrosis Targeted Drug Market ($B) by Type
Figure 4.3: Forecast for the Global Myelofibrosis Targeted Drug Market ($B) by Type
Figure 4.4: Trends and Forecast for Ruxolitinib in the Global Myelofibrosis Targeted Drug Market (2019-2031)
Figure 4.5: Trends and Forecast for Jaktinib in the Global Myelofibrosis Targeted Drug Market (2019-2031)
Figure 4.6: Trends and Forecast for Fedratinib in the Global Myelofibrosis Targeted Drug Market (2019-2031)
Figure 4.7: Trends and Forecast for Pacritinib in the Global Myelofibrosis Targeted Drug Market (2019-2031)
Figure 4.8: Trends and Forecast for Others in the Global Myelofibrosis Targeted Drug Market (2019-2031)
Figure 5.1: Global Myelofibrosis Targeted Drug Market by Application in 2019, 2024, and 2031
Figure 5.2: Trends of the Global Myelofibrosis Targeted Drug Market ($B) by Application
Figure 5.3: Forecast for the Global Myelofibrosis Targeted Drug Market ($B) by Application
Figure 5.4: Trends and Forecast for Primary Myelofibrosis in the Global Myelofibrosis Targeted Drug Market (2019-2031)
Figure 5.5: Trends and Forecast for Secondary Myelofibrosis in the Global Myelofibrosis Targeted Drug Market (2019-2031)
Figure 6.1: Trends of the Global Myelofibrosis Targeted Drug Market ($B) by Region (2019-2024)
Figure 6.2: Forecast for the Global Myelofibrosis Targeted Drug Market ($B) by Region (2025-2031)
Figure 7.1: North American Myelofibrosis Targeted Drug Market by type in 2019, 2024, and 2031
Figure 7.2: Trends of the North American Myelofibrosis Targeted Drug Market ($B) by type (2019-2024)
Figure 7.3: Forecast for the North American Myelofibrosis Targeted Drug Market ($B) by type (2025-2031)
Figure 7.4: North American Myelofibrosis Targeted Drug Market by application in 2019, 2024, and 2031
Figure 7.5: Trends of the North American Myelofibrosis Targeted Drug Market ($B) by application (2019-2024)
Figure 7.6: Forecast for the North American Myelofibrosis Targeted Drug Market ($B) by application (2025-2031)
Figure 7.7: Trends and Forecast for the United States Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 7.8: Trends and Forecast for the Mexican Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 7.9: Trends and Forecast for the Canadian Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 8.1: European Myelofibrosis Targeted Drug Market by type in 2019, 2024, and 2031
Figure 8.2: Trends of the European Myelofibrosis Targeted Drug Market ($B) by type (2019-2024)
Figure 8.3: Forecast for the European Myelofibrosis Targeted Drug Market ($B) by type (2025-2031)
Figure 8.4: European Myelofibrosis Targeted Drug Market by application in 2019, 2024, and 2031
Figure 8.5: Trends of the European Myelofibrosis Targeted Drug Market ($B) by application (2019-2024)
Figure 8.6: Forecast for the European Myelofibrosis Targeted Drug Market ($B) by application (2025-2031)
Figure 8.7: Trends and Forecast for the German Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 8.8: Trends and Forecast for the French Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 8.9: Trends and Forecast for the Spanish Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 8.10: Trends and Forecast for the Italian Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 8.11: Trends and Forecast for the United Kingdom Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 9.1: APAC Myelofibrosis Targeted Drug Market by type in 2019, 2024, and 2031
Figure 9.2: Trends of the APAC Myelofibrosis Targeted Drug Market ($B) by type (2019-2024)
Figure 9.3: Forecast for the APAC Myelofibrosis Targeted Drug Market ($B) by type (2025-2031)
Figure 9.4: APAC Myelofibrosis Targeted Drug Market by application in 2019, 2024, and 2031
Figure 9.5: Trends of the APAC Myelofibrosis Targeted Drug Market ($B) by application (2019-2024)
Figure 9.6: Forecast for the APAC Myelofibrosis Targeted Drug Market ($B) by application (2025-2031)
Figure 9.7: Trends and Forecast for the Japanese Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 9.8: Trends and Forecast for the Indian Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 9.9: Trends and Forecast for the Chinese Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 9.10: Trends and Forecast for the South Korean Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 9.11: Trends and Forecast for the Indonesian Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 10.1: ROW Myelofibrosis Targeted Drug Market by type in 2019, 2024, and 2031
Figure 10.2: Trends of the ROW Myelofibrosis Targeted Drug Market ($B) by type (2019-2024)
Figure 10.3: Forecast for the ROW Myelofibrosis Targeted Drug Market ($B) by type (2025-2031)
Figure 10.4: ROW Myelofibrosis Targeted Drug Market by application in 2019, 2024, and 2031
Figure 10.5: Trends of the ROW Myelofibrosis Targeted Drug Market ($B) by application (2019-2024)
Figure 10.6: Forecast for the ROW Myelofibrosis Targeted Drug Market ($B) by application (2025-2031)
Figure 10.7: Trends and Forecast for the Middle Eastern Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 10.8: Trends and Forecast for the South American Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 10.9: Trends and Forecast for the African Myelofibrosis Targeted Drug Market ($B) (2019-2031)
Figure 11.1: Porter's Five Forces Analysis of the Global Myelofibrosis Targeted Drug Market
Figure 11.2: Market Share (%) of Top Players in the Global Myelofibrosis Targeted Drug Market (2024)
Figure 12.1: Growth Opportunities for the Global Myelofibrosis Targeted Drug Market by Type
Figure 12.2: Growth Opportunities for the Global Myelofibrosis Targeted Drug Market by Application
Figure 12.3: Growth Opportunities for the Global Myelofibrosis Targeted Drug Market by Region
Figure 12.4: Emerging Trends in the Global Myelofibrosis Targeted Drug Market

List of Tables

Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Myelofibrosis Targeted Drug Market by Type and Application
Table 1.2: Attractiveness Analysis for the Myelofibrosis Targeted Drug Market by Region
Table 1.3: Global Myelofibrosis Targeted Drug Market Parameters and Attributes
Table 3.1: Trends of the Global Myelofibrosis Targeted Drug Market (2019-2024)
Table 3.2: Forecast for the Global Myelofibrosis Targeted Drug Market (2025-2031)
Table 4.1: Attractiveness Analysis for the Global Myelofibrosis Targeted Drug Market by Type
Table 4.2: Market Size and CAGR of Various Type in the Global Myelofibrosis Targeted Drug Market (2019-2024)
Table 4.3: Market Size and CAGR of Various Type in the Global Myelofibrosis Targeted Drug Market (2025-2031)
Table 4.4: Trends of Ruxolitinib in the Global Myelofibrosis Targeted Drug Market (2019-2024)
Table 4.5: Forecast for Ruxolitinib in the Global Myelofibrosis Targeted Drug Market (2025-2031)
Table 4.6: Trends of Jaktinib in the Global Myelofibrosis Targeted Drug Market (2019-2024)
Table 4.7: Forecast for Jaktinib in the Global Myelofibrosis Targeted Drug Market (2025-2031)
Table 4.8: Trends of Fedratinib in the Global Myelofibrosis Targeted Drug Market (2019-2024)
Table 4.9: Forecast for Fedratinib in the Global Myelofibrosis Targeted Drug Market (2025-2031)
Table 4.10: Trends of Pacritinib in the Global Myelofibrosis Targeted Drug Market (2019-2024)
Table 4.11: Forecast for Pacritinib in the Global Myelofibrosis Targeted Drug Market (2025-2031)
Table 4.12: Trends of Others in the Global Myelofibrosis Targeted Drug Market (2019-2024)
Table 4.13: Forecast for Others in the Global Myelofibrosis Targeted Drug Market (2025-2031)
Table 5.1: Attractiveness Analysis for the Global Myelofibrosis Targeted Drug Market by Application
Table 5.2: Market Size and CAGR of Various Application in the Global Myelofibrosis Targeted Drug Market (2019-2024)
Table 5.3: Market Size and CAGR of Various Application in the Global Myelofibrosis Targeted Drug Market (2025-2031)
Table 5.4: Trends of Primary Myelofibrosis in the Global Myelofibrosis Targeted Drug Market (2019-2024)
Table 5.5: Forecast for Primary Myelofibrosis in the Global Myelofibrosis Targeted Drug Market (2025-2031)
Table 5.6: Trends of Secondary Myelofibrosis in the Global Myelofibrosis Targeted Drug Market (2019-2024)
Table 5.7: Forecast for Secondary Myelofibrosis in the Global Myelofibrosis Targeted Drug Market (2025-2031)
Table 6.1: Market Size and CAGR of Various Regions in the Global Myelofibrosis Targeted Drug Market (2019-2024)
Table 6.2: Market Size and CAGR of Various Regions in the Global Myelofibrosis Targeted Drug Market (2025-2031)
Table 7.1: Trends of the North American Myelofibrosis Targeted Drug Market (2019-2024)
Table 7.2: Forecast for the North American Myelofibrosis Targeted Drug Market (2025-2031)
Table 7.3: Market Size and CAGR of Various type in the North American Myelofibrosis Targeted Drug Market (2019-2024)
Table 7.4: Market Size and CAGR of Various type in the North American Myelofibrosis Targeted Drug Market (2025-2031)
Table 7.5: Market Size and CAGR of Various application in the North American Myelofibrosis Targeted Drug Market (2019-2024)
Table 7.6: Market Size and CAGR of Various application in the North American Myelofibrosis Targeted Drug Market (2025-2031)
Table 7.7: Trends and Forecast for the United States Myelofibrosis Targeted Drug Market (2019-2031)
Table 7.8: Trends and Forecast for the Mexican Myelofibrosis Targeted Drug Market (2019-2031)
Table 7.9: Trends and Forecast for the Canadian Myelofibrosis Targeted Drug Market (2019-2031)
Table 8.1: Trends of the European Myelofibrosis Targeted Drug Market (2019-2024)
Table 8.2: Forecast for the European Myelofibrosis Targeted Drug Market (2025-2031)
Table 8.3: Market Size and CAGR of Various type in the European Myelofibrosis Targeted Drug Market (2019-2024)
Table 8.4: Market Size and CAGR of Various type in the European Myelofibrosis Targeted Drug Market (2025-2031)
Table 8.5: Market Size and CAGR of Various application in the European Myelofibrosis Targeted Drug Market (2019-2024)
Table 8.6: Market Size and CAGR of Various application in the European Myelofibrosis Targeted Drug Market (2025-2031)
Table 8.7: Trends and Forecast for the German Myelofibrosis Targeted Drug Market (2019-2031)
Table 8.8: Trends and Forecast for the French Myelofibrosis Targeted Drug Market (2019-2031)
Table 8.9: Trends and Forecast for the Spanish Myelofibrosis Targeted Drug Market (2019-2031)
Table 8.10: Trends and Forecast for the Italian Myelofibrosis Targeted Drug Market (2019-2031)
Table 8.11: Trends and Forecast for the United Kingdom Myelofibrosis Targeted Drug Market (2019-2031)
Table 9.1: Trends of the APAC Myelofibrosis Targeted Drug Market (2019-2024)
Table 9.2: Forecast for the APAC Myelofibrosis Targeted Drug Market (2025-2031)
Table 9.3: Market Size and CAGR of Various type in the APAC Myelofibrosis Targeted Drug Market (2019-2024)
Table 9.4: Market Size and CAGR of Various type in the APAC Myelofibrosis Targeted Drug Market (2025-2031)
Table 9.5: Market Size and CAGR of Various application in the APAC Myelofibrosis Targeted Drug Market (2019-2024)
Table 9.6: Market Size and CAGR of Various application in the APAC Myelofibrosis Targeted Drug Market (2025-2031)
Table 9.7: Trends and Forecast for the Japanese Myelofibrosis Targeted Drug Market (2019-2031)
Table 9.8: Trends and Forecast for the Indian Myelofibrosis Targeted Drug Market (2019-2031)
Table 9.9: Trends and Forecast for the Chinese Myelofibrosis Targeted Drug Market (2019-2031)
Table 9.10: Trends and Forecast for the South Korean Myelofibrosis Targeted Drug Market (2019-2031)
Table 9.11: Trends and Forecast for the Indonesian Myelofibrosis Targeted Drug Market (2019-2031)
Table 10.1: Trends of the ROW Myelofibrosis Targeted Drug Market (2019-2024)
Table 10.2: Forecast for the ROW Myelofibrosis Targeted Drug Market (2025-2031)
Table 10.3: Market Size and CAGR of Various type in the ROW Myelofibrosis Targeted Drug Market (2019-2024)
Table 10.4: Market Size and CAGR of Various type in the ROW Myelofibrosis Targeted Drug Market (2025-2031)
Table 10.5: Market Size and CAGR of Various application in the ROW Myelofibrosis Targeted Drug Market (2019-2024)
Table 10.6: Market Size and CAGR of Various application in the ROW Myelofibrosis Targeted Drug Market (2025-2031)
Table 10.7: Trends and Forecast for the Middle Eastern Myelofibrosis Targeted Drug Market (2019-2031)
Table 10.8: Trends and Forecast for the South American Myelofibrosis Targeted Drug Market (2019-2031)
Table 10.9: Trends and Forecast for the African Myelofibrosis Targeted Drug Market (2019-2031)
Table 11.1: Product Mapping of Myelofibrosis Targeted Drug Suppliers Based on Segments
Table 11.2: Operational Integration of Myelofibrosis Targeted Drug Manufacturers
Table 11.3: Rankings of Suppliers Based on Myelofibrosis Targeted Drug Revenue
Table 12.1: New Product Launches by Major Myelofibrosis Targeted Drug Producers (2019-2024)
Table 12.2: Certification Acquired by Major Competitor in the Global Myelofibrosis Targeted Drug Market

02-2729-4219

+886-2-2729-4219

License/價格

FAQ

骨髓纖維化治療市場報告：2031 年趨勢、預測與競爭分析

Myelofibrosis Targeted Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

目錄

第1章執行摘要

第2章 市場概況

第3章：市場趨勢及預測分析

4. 全球骨髓纖維化藥物市場（按類型）

5. 全球骨髓纖維化藥物市場（依應用）

第6章 區域分析

7.北美骨髓纖維化治療市場

8.歐洲骨髓纖維化藥物市場

9. 亞太地區骨髓纖維化藥物市場

10. 其他地區骨髓纖維化治療市場

第11章 競爭分析

第12章：機會與策略分析

第13章 價值鏈主要企業的公司簡介

第14章 附錄